All News

CPPDwrist.JPG

IL-1 Inhibition in CPPD

Jack Cush, MD

Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares.

Read Article
Sjogren_syndrome_salivary%20bx%282%29.jpg

DAHLIAS study - Nipocalimab in Sjögren's Disease

Jack Cush, MD

Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease.

Read Article
Stevens-johnson-syndrome.jpg

Genetic Risks and Severe Cutaneous Reactions to Allopurinol

Jack Cush, MD

A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those affected, suggesting these are strong but incomplete indicators of SCAR risk. 

Read Article
ACR, guidance, guidelines

New ACR 2025 Guidelines for Non-Renal Lupus

MedPage Today

Written by Lisa Sammaritano, MD, of the Hospital for Special Surgery in New York City, and a committee of nearly 50 other experts, the new guideline also stipulates that corticosteroids are OK for gaining symptom control in newly diagnosed patients and when flares erupt, but the duration should be kept as short as possible.

Read Article
FDG,PET,CT

PET Uptake in Large Vessel GCA – Does tocilizumab help?

Brian Jaros, MD

Giant cell arteritis (GCA) is the most common form of adult vasculitis in the United States and can be subdivided into those with cranial only symptoms, those with large vessel vasculiti/PMR, and those with mixed features.

Read Article
Cush and Kavanaugh

ACR 2025 Rheumatology Round Up

Jack Cush, MD

Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.

Read Article
acr_session2.jpeg

ACR25 Best Abstracts - Day 4

Jack Cush, MD

Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty.  Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!

Read Article
RheumNow Podcast square

Halloween ACR Guidance (10.31.25)

Jack Cush, MD

Dr. Jack Cush recaps ACR2025 with suggestions on how to best learn ACR25 content from RheumNow.com and our articles, videos and podcasts.

Read Article
Genetic Risks and Severe Cutaneous Reactions to Allopurinol A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww
Dr. John Cush RheumNow ( View Tweet)
Combining CAR-T with CAR-Treg All in One Dr. Alfred Kim reports on abstract 0981 (GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases). https://t.co/SXuLYyUCXo https://t.co/5CAzoGfOyf

Links:

Dr. John Cush RheumNow ( View Tweet)
Stopping therapy in GCA At #ACR25 we saw the SELECT-GCA extension data presented in the first plenary session, looking at the second year after the 52 week original study, comparing upadacitinib versus placebo in GCA. In this second year, patients in remission on upadacitinib https://t.co/GaYNWr3Sjq
Dr. John Cush RheumNow ( View Tweet)
Belimumab Before or After Immunosuppressant Dr. Yuz Yusof reports on abstract 0803 presented at #ACR25 https://t.co/BVFhDDfTvW https://t.co/F9ZvGXIqVn

Links:

Dr. John Cush RheumNow ( View Tweet)
Are we putting the CAR-T before the horse? CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure. https://t.co/niPU5cAojP
Dr. John Cush RheumNow ( View Tweet)
B Cell Depletion: Check the Lymph Node Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents) presented at #ACR25. https://t.co/BjgIC3Kng0 https://t.co/flfyLZYW8q

Links:

Dr. John Cush RheumNow ( View Tweet)
🍼 “Stop breastfeeding if on methotrexate” — that’s what we’ve always heard. But here’s the news 👇 📊 Latest EULAR lactation: Methotrexate = LoE 4 / C ➡️ May be considered in breastfeeding if no safer alternative exists. 💡Not first-line, not forbidden — just evidence-limited. https://t.co/IJEpZYMaFV

Links:

Dr Abhilasha Manwatkar (AIIMS Nagpur) Abhilasha21822 ( View Tweet)
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus 📄 Read the paper: https://t.co/56eOK86lmn ℹ️ See additional content and resources on this guideline at https://t.co/PVEyOkY14w https://t.co/cR4RVfWPlI

Links:

ACR_Journals ACR_Journals ( View Tweet)
SLE Conference Preview: progress in biologics at #ACR25 We now have four licensed targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis and belimumab and anifrolumab for active non-renal SLE). What are other issues to be addressed and https://t.co/uvVICAsCzo
Dr. John Cush RheumNow ( View Tweet)
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE Dr. Sheila Reyes reports on the scientific session presentation of the #ACR25 treatment guidelines for SLE https://t.co/Bh1fSFf8ju https://t.co/OH8h9GDeMf

Links:

Dr. John Cush RheumNow ( View Tweet)
Day 1 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope, and Jack Cush for Day 1 highlights from the 2025 ACR Convergence in Chicago, focusing on abstracts/sessions: 0775, SLE guidelines, 0163, 0832, 0776, 0792, and 0164. https://t.co/ODte4XY82a
Dr. John Cush RheumNow ( View Tweet)
Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x Great discussion by @EBRheum @AkhilSoodMD @Dr_Brian_MD . I have always been a FK fan in lupus nephritis as an add on therapy , the only inconvenience is regular monitoring. @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×